We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.
- Authors
Okada, Masahiro; Imai, Yasuharu; Kim, Tonsok; Kogita, Sachiyo; Takamura, Manabu; Kumano, Seishi; Onishi, Hiromitsu; Hori, Masatoshi; Fukuda, Kazuto; Hayashi, Norio; Wakasa, Kenichi; Sakamoto, Michiie; Murakami, Takamichi
- Abstract
Purpose To compare enhancenent patterns of hepatocellular carcinoma (HCC) and dysplastic nodule (DN) between gadoxetate- and ferucarbotran-enhanced MRI. Materials and Methods Patients recruited from ultrasound surveillance for HCC in chronic liver diseases were enrolled in this prospective study approved by institutional review board. Thirty-six patients with 37 histologically proven HCC, including 22 well-differentiated HCCs (wHCC), 15 moderately to poorly differentiated HCCs (mpHCCs), and 4 DNs, underwent gadoxetate-enhanced and ferucarbotran-enhanced MRI. We compared hepatobiliary phase image of gadoxetate-enhanced MRI with ferucarbotran-enhanced MR image regarding signal intensity of HCC and DN relative to surrounding liver parenchyma. We calculated contrast ratios between tumor and liver on pre-enhancement, hepatobiliary phase of gadoxetate-enhanced MRI and ferucarbotran-enhanced MRI. Results On ferucarbotran-enhanced MRI, all mpHCCs showed hyper-intensity, while 14 wHCCs (14/22;63%) showed iso-intensity. On hepatobiliary phase of gadoxetate-enhanced MRI, 13 mpHCCs (13/15;86%) and 20 wHCCs (20/22;91%) showed hypo-intensity. Two DNs and the other two showed iso- and hypo-intensity, respectively, on gadoxetate-enhanced MRI, whereas all DNs revealed iso-intensity on ferucarbotran-enhanced MRI. Gadoxetate-postcontrast ratio was significantly lower than ferucarbotran-postcontrast ratio in wHCC ( P = 0.015). Conclusion The uptake function of hepatocytes that are targeted by gadoxetate is more sensitive than that of Kupffer cells targeted by ferucarbotran in stepwise hepatocarcinogenesis. J. Magn. Reson. Imaging 2010;32:903-913. © 2010 Wiley-Liss, Inc.
- Publication
Journal of Magnetic Resonance Imaging, 2010, Vol 32, Issue 4, p903
- ISSN
1053-1807
- Publication type
Article
- DOI
10.1002/jmri.22333